NCT05669456 (ZASH) is a clinical trial of Halo Alert System in Acute Ischemic Stroke, sponsored by Zeit Medical, Inc..

Who is sponsoring NCT05669456?

NCT05669456 is sponsored by Zeit Medical, Inc..

What drugs are being tested in NCT05669456?

Interventions in NCT05669456: Halo Alert System.

What condition does NCT05669456 study?

NCT05669456 studies Acute Ischemic Stroke, Ischemic Stroke, Stroke.

Is NCT05669456 still recruiting?

NCT05669456 is currently status unknown. Last updated 30 December 2022.

Last reviewed 2022-12-30 · How we verify

NCT05669456: ZASH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zeit Alert for Stroke at Home (ZASH) Protocol

Status unknown Last updated 30 December 2022

What this trial tests

trial testing Halo Alert System in Acute Ischemic Stroke in 300 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
30 June 2024

30 September 2024

Quick facts

Lead sponsor	Zeit Medical, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 January 2023
Primary completion	30 June 2024
Estimated completion	30 September 2024

Drugs / interventions tested

Halo Alert System

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Ischemic Stroke — all drugs for Ischemic Stroke →
Stroke — all drugs for Stroke →

Sponsor

Zeit Medical, Inc.

Who can join

18 and older, any sex, with Acute Ischemic Stroke or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, observational, feasibility study to evaluate if the Halo Alert System can be used in the future to detect stroke events in individuals at risk for stroke wearing the Halo Alert System overnight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05669456 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zeit Medical, Inc.
Last refreshed: 30 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05669456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing